5/1/2014 2:06:20 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals Inc. today announced the presentation of preclinical data demonstrating the mechanism of action for CAT-2003. The data were presented by Michael Zimmer, Ph.D., in an oral session at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions. The data demonstrate that CAT-2003 inhibits the transcription factor Sterol Regulatory Element Binding Protein (SREBP) in vitro and in vivo, resulting in the reduced expression of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), which normally acts to increase low-density lipoprotein (LDL) cholesterol. CAT-2003 currently is in a Phase 2 clinical trial for the treatment of patients with severe hypertriglyceridemias, including rare chylomicronemia syndromes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by